Presence of benzimidazole nucleus in numerous categories of therapeutic agents such as
antimicrobials, antivirals, antiparasites, anticancer, anti-inflammatory, antioxidants, proton …

This review provides an overview of stearoyl-coenzyme A desaturase-1 (SCD1) as a novel
therapeutic target for metabolic disorders and other indications. Target validation is …

We investigated the catalytic efficacy of supported gold nanoparticles (AuNPs) towards the
selective reaction between o-phenylenediamine and aldehydes that yields 2-substituted …

Stearoyl-CoA desaturase (SCD) is a potential therapeutic target for Parkinson's and related
neurodegenerative diseases. SCD inhibition ameliorates neuronal toxicity caused by …

Two sets of benzimidazole derivatives were synthesised and tested in vitro for activity
against promastigotes of Leishmania tropica and L. infantum. Most of the tested compounds …

Here we present an innovative computational-based drug discovery strategy, coupled with
machine-based learning and functional assessment, for the rational design of novel small …

Inhibition of stearoyl-CoA desaturase (SCD) activity represents a potential novel mechanism
for the treatment of metabolic disorders including obesity and type II diabetes. To circumvent …

Benzimidazoles are classified as a category of heterocyclic compounds. They possess an
essential structural feature of 6-membered benzene fused to 5-membered imidazole moiety …

Introduction: Stearoyl coenzyme-A desaturase (SCD) is a critical lipogenic enzyme that
converts a range of unsaturated lipids to their corresponding monounsaturated fatty acids …

Expansion of the 6-membered ring and subsequent fine-tuning of the newly obtained 7-
membered spiropiperidine structure resulted in the discovery of a series of novel and potent …